The Kidney Innovation Accelerator (KidneyX), a public-private partnership between the U.S. Department of Health and Human Services (HHS) and the American Society of Nephrology (ASN), is accelerating innovation in the prevention, diagnosis, and treatment of kidney diseases.
The Artificial Kidney Prize is a competition to accelerate the development of continuous kidney replacement therapies that provide transformational treatment options beyond current dialysis methods. For this competition, artificial kidneys may be wearable, implantable, bioengineered, developed as a xenotransplant or chimera organ, or other approaches not yet conceived. Phase 1 seeks demonstrated scientific and technical proofs of concept with detailed development plans for solutions that enable and advance the functionality, effectiveness, and/or reliability of artificial kidneys. Phase 2 will focus on initial integration of prototype solutions into an artificial kidney, or advancement of already integrated prototype solutions.
The competition will award up to $10 million. Up to $4 million in Phase 1 prizes will be distributed among up to eight Phase 1 winners, at the discretion of HHS and ASN. For Phase 2, up to $6 million in prizes will be distributed to winners at the discretion of HHS and ASN. Up to $2.5 million in prizes will be awarded by HHS over Phases 1-2; up to $7.5 million in prizes will be awarded by ASN over Phases 1-2.
Deadline for Phase 1: March 24, 2021
The Artificial Kidney Prize is open to both U.S. and international entrants, subject to eligibility requirements.
